VISEN Pharmaceuticals, an SIP-headquartered innovative biopharmaceutical company focused on endocrine diseases, announced on Jan 26 that the National Medical Products Administration of China had approved the market launch of its core product, SKYTROFA (lonapegsomatropin for injection). As the first and the only long-acting growth hormone clinically proven superior to daily formulations in China, this new drug offers a better treatment option for patients with growth hormone deficiency, and marks another major achievement in innovative drug development within SIP.
Founded by Vivo Capital, one of the world’s largest healthcare-focused investment firms, and Danish biopharmaceutical company Ascendis, VISEN Pharmaceuticals specializes in endocrine-related therapies and is committed to developing first-in-class or best-in-class treatments. With its China headquarters and global core base for long-acting growth hormone in SIP, the company was listed on the Main Board of the HKEX last year.
Based on innovative TransCon technology, SKYTROFA enables once-weekly dosing through a controlled-release mechanism, overcoming the limitations of traditional daily injections. Clinical studies have confirmed its significantly better efficacy and patient compliance compared to short-acting growth hormones, effectively addressing growth delays in children.
January 28, 2026
